Physician profile
Joseph Sweeny
NPI 1841465234
$30,066.67
in general payments reported to CMS, 2019-2025
17 companies · $12K in 2025
The $12K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $353 · 2021: $1,413 · 2022: $6,891 · 2023: $243 · 2024: $8,541 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,300 · Food and Beverage: $726 · Travel and Lodging: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,450.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,300.00 |
| Food and Beverage | $726.19 |
| Travel and Lodging | $347.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28,401.93 | 2021-2025 | Optis, Coroflow, Pressurewire |
| Boston Scientific Corporation | $476.48 | 2019-2021 | |
| Chiesi USA, INC. | $250.36 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $219.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $166.32 | 2020-2022 | |
| Amgen INC. | $116.13 | 2021-2025 | |
| Terumo Medical Corporation | $87.71 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $74.89 | 2022 | |
| Medtronic, INC. | $59.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $55.55 | 2020-2021 | |
| Philips North America LLC | $35.34 | 2020 | |
| Abiomed | $33.35 | 2020 | |
| Shockwave Medical, INC | $28.52 | 2021 | |
| Penumbra, INC. | $22.30 | 2020 | |
| Pfizer INC. | $21.41 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $17.31 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sweeny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.